Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Summary

This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated.

Timeline

Start

2017-08-28

Primary completion

2021-08-11

Completion

2024-03-31

Drugs

Indications